Viking Therapeutics, Inc. $VKTX Shares Bought by Concurrent Investment Advisors LLC

Concurrent Investment Advisors LLC raised its position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) by 5.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,590 shares of the biotechnology company’s stock after buying an additional 488 shares during the period. Concurrent Investment Advisors LLC’s holdings in Viking Therapeutics were worth $254,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Cambridge Investment Research Advisors Inc. boosted its position in shares of Viking Therapeutics by 121.5% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 29,721 shares of the biotechnology company’s stock worth $718,000 after buying an additional 16,302 shares during the period. Wealth Management Associates Inc. purchased a new position in shares of Viking Therapeutics during the first quarter worth $241,000. Kingstone Capital Partners Texas LLC purchased a new position in shares of Viking Therapeutics during the second quarter worth $1,367,000. U.S. Capital Wealth Advisors LLC boosted its position in shares of Viking Therapeutics by 77.7% during the second quarter. U.S. Capital Wealth Advisors LLC now owns 63,546 shares of the biotechnology company’s stock worth $1,684,000 after buying an additional 27,795 shares during the period. Finally, Wesbanco Bank Inc. boosted its position in shares of Viking Therapeutics by 118.5% during the second quarter. Wesbanco Bank Inc. now owns 52,000 shares of the biotechnology company’s stock worth $1,378,000 after buying an additional 28,200 shares during the period. 76.03% of the stock is currently owned by hedge funds and other institutional investors.

Viking Therapeutics Price Performance

Viking Therapeutics stock opened at $33.75 on Tuesday. Viking Therapeutics, Inc. has a 1-year low of $18.92 and a 1-year high of $81.73. The stock has a market cap of $3.79 billion, a PE ratio of -22.06 and a beta of 0.64. The stock’s fifty day moving average is $29.14 and its two-hundred day moving average is $28.49.

Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings results on Wednesday, July 23rd. The biotechnology company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.14). During the same quarter in the prior year, the business posted ($0.20) earnings per share. The firm’s quarterly revenue was up NaN% on a year-over-year basis. On average, research analysts expect that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. HC Wainwright restated a “buy” rating and set a $102.00 price target on shares of Viking Therapeutics in a research report on Monday, September 29th. BTIG Research restated a “buy” rating and set a $125.00 price target on shares of Viking Therapeutics in a research report on Monday, September 22nd. Citigroup raised their price target on Viking Therapeutics from $31.00 to $38.00 and gave the stock a “neutral” rating in a research report on Thursday, July 24th. Raymond James Financial decreased their target price on Viking Therapeutics from $125.00 to $122.00 and set a “strong-buy” rating for the company in a report on Thursday, July 24th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Viking Therapeutics in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $86.42.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.